Strategy's BTC flywheel stalls; $20B M&A lands over weekend — whale moves Jun 19–22

Three and a half days of SEC filings hit the queue this Monday morning — Friday afternoon through the weekend — producing one of the heavier single-batch opens of the month. The headline is Strategy (MSTR), where 520 BTC bought last week is the smallest weekly purchase since at least March 2026. But the machine kept selling shares: $335.5 million in new stock went out the door while only $34.9 million came back as bitcoin. The gap is going to cash, not to BTC. Alongside that, AbbVie agreed to pay $10.9 billion for a biotech, CRH lined up an $8.5 billion infrastructure acquisition, SpaceX disclosed $100.8 billion in cash and opened its debut bond deal, and Booz Allen dropped $720 million on a defense tech shop. Thirteen of the twenty-one watchlist tickers showed no new filings; three critical overdue items remain open.

Strategy's 8-K filed Monday morning reports 520 BTC acquired during June 15–21 for $34.9 million at an average of $67,068 per BTC. 1 Total holdings now stand at 847,363 BTC, carried at an aggregate cost of $64.10 billion ($75,651/BTC average). 2

The deceleration in buying is sharp. Strategy purchased 34,164 BTC worth $2.54 billion in April 2026 and 24,869 BTC worth $2.01 billion in May. Weekly volume then fell to 1,550 BTC ($101 million) for the first week of June, roughly flat at 1,587 BTC ($100 million) the following week, and collapsed to 520 BTC ($35 million) in the most recent period — a 98.6% decline from the April peak. 2

While BTC buying slumped, ATM share issuance accelerated. Strategy sold 2,714,839 MSTR Class A shares during June 15–21, generating $335.5 million in net proceeds — up 56.7% from the prior week's 1,732,553 shares ($209 million). 1 Of that $335.5 million, only $34.9 million (about 10.4%) went toward bitcoin; the rest flowed into a cash reserve that grew $300 million week-over-week to $1.4 billion. The reserve is designated to support preferred stock dividends and debt interest. Remaining MSTR ATM capacity stands at $25.411 billion as of June 21. 1

No preferred shares (STRF, STRC, STRK, STRD) were sold during the period; all issuance was concentrated in MSTR common stock.

The funding channel behind Strategy's BTC accumulation has been misfiring. STRC — Strategy's floating-rate perpetual preferred stock with a $100 par value and 11.5% annual dividend — fell to a record low of $82.53 on June 19 before closing at $88.59 on June 20. 3 Trading below $89 triggers automatic dividend rate increases on existing issued shares, adding roughly $53 million per year to Strategy's dividend obligations. 4

Strategy carries $8.17 billion in long-term debt and $229.53 million in quarterly preferred dividend obligations. Earlier in June it sold 32 BTC for approximately $2.5 million — the first BTC sale since 2022 — to help cover those payments. 5

At current BTC prices around $62,875 (implied from the Strategy.com dashboard as of June 21), the portfolio sits roughly $12,776 below Strategy's average cost basis of $75,651, an unrealized mark-to-market gap across the full 847,363-BTC position. 2

Opinion is divided on what this means. Jesse Myers of The Smarter Web Company argued Strategy "is fine" — the company can fund STRC dividends for 32 years at current conditions, and indefinitely if BTC appreciates at roughly 2% annually. 4 Bloomberg ETF analyst Eric Balchunas called STRC a "constant headache" and argued Strategy should abandon these funding instruments. 3 Alex Sirois at 24/7 Wall St. wrote: "At $116.56, Strategy Inc. (NASDAQ:MSTR) looks vulnerable, with dilutive equity issuance colliding with a hawkish incoming Fed under Kevin Warsh setting up a potential path back toward $65." 5

Three major corporate acquisitions filed across Friday–Monday, covering healthcare, infrastructure, and defense technology.

AbbVie / Apogee ($10.9B): AbbVie (NYSE: ABBV) agreed June 18 to acquire Apogee Therapeutics (Nasdaq: APGE) at $135.11 per share in cash, valuing Apogee at approximately $10.9 billion. The deal closes through a subsidiary merger (Andor Merger Co. into Apogee); both boards unanimously approved it with no financing condition. 6 The strategic target is Apogee's immunology pipeline: zumilokibart (APG777), being developed for atopic dermatitis and asthma, plus combination program APG273. AbbVie described potential "mega-blockbuster" peak sales and expects the acquisition to be accretive to adjusted diluted EPS beginning in 2032. Subject to Apogee stockholder approval and HSR antitrust clearance; reciprocal termination fees of $381.3 million apply.

CRH / Arcosa ($8.5B): CRH Americas (subsidiary of CRH plc, NYSE: CRH) agreed June 21 to acquire Arcosa (NYSE: ACA) — a Dallas-based infrastructure and construction materials company — at $150.00 per share in cash. Enterprise value is approximately $8.5 billion, representing a 25% premium to Arcosa's 60-day VWAP as of June 18. 7 The deal prices at 11.5× 2026E Adjusted EBITDA including $175 million in estimated annual run-rate synergies by year three. Pro forma leverage is 2.4× net debt / adjusted EBITDA. Arcosa common stock will be delisted upon completion. Subject to ACA majority shareholder approval, HSR clearance, and other regulatory approvals; outside date June 21, 2027 (extendable six months for unresolved regulatory issues).

Booz Allen / Ultra Mission Solutions ($720M): Booz Allen Hamilton (NYSE: BAH) agreed Monday to acquire Ultra I&C Mission Solutions from Advent International's Cobham Ultra Group for $720 million in a stock purchase. 8 Ultra Mission Solutions — headquartered in Austin, TX, with roughly 220 employees including ~135 specialized engineers — develops mission-critical software, encryption products, and edge-compute systems (branded Apex, ADSI, ACTS, Rain, Knox). BAH expects strong double-digit revenue growth for several years post-close, with EBITDA margins "well above 20%." Close targeted for Q2 of Booz Allen's FY2027 (by September 30, 2026), subject to HSR clearance. Booz Allen Chairman and CEO Horacio Rozanski said the company is "strategically investing to accelerate delivery of our defense tech products into national security missions." 8

Space Exploration Technologies Corp. (Nasdaq: SPCX) filed an 8-K Monday morning commencing its inaugural offering of senior unsecured notes — the company's first-ever bond sale. 9 To prospective note investors, SpaceX disclosed holding approximately $100.8 billion in cash and cash equivalents as of June 19, 2026. 9

The notes will rank equally with all existing and future unsubordinated debt. Proceeds are designated primarily to repay a bridge loan facility in full, with the remainder for general corporate purposes. The offering is structured for qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S; the notes are not registered under the Securities Act. CFO Bret Johnsen signed the filing. Timing and pricing depend on market conditions.

A company with $100.8 billion in cash choosing to borrow for the first time invites scrutiny of the structure: the bridge loan repayment use-of-proceeds suggests SpaceX may have drawn the bridge in connection with a prior investment or acquisition (not yet publicly disclosed in this filing), and the inaugural bond is the permanent capital replacement.

Quantinuum (QNT) — Cambridge Quantum 71.5% stake disclosed: Cambridge Quantum Holdings Limited, its controlling shareholder Ilyas Khan, and Waseem Shiraz filed a Schedule 13G on June 22 disclosing beneficial ownership of 82,884,823 shares of Quantinuum's Class A common stock — approximately 71.5% on a conversion basis per the issuer's June 3, 2026 IPO prospectus. 10 Cambridge Quantum directly holds 82,353,103 Common Units (convertible 1:1 into Class A shares); CQ Invest I LLC holds the balance. The filing is classified as a passive investor disclosure (13G), signaling no current intent to influence governance. Quantinuum (Nasdaq: QNT), a quantum computing company, went public in early June 2026 — this is the first major ownership disclosure since the IPO.

Innate Pharma (IPHA) — Novo Nordisk full exit: Novo Nordisk A/S (signed by CFO Karsten Munk Knudsen) filed Schedule 13G/A Amendment No. 4 on June 22 reporting 0 shares and 0.00% beneficial ownership in Innate Pharma SA (Nasdaq: IPHA). 11 The event date was May 29. Innate Pharma is a French immuno-oncology company; Novo Nordisk had held a passive stake as a strategic partner. The complete exit removes Novo from the company's shareholder base with no stated reason disclosed in the filing.

Lucid (LCID) — 18% US workforce cut, COO role eliminated: Lucid Group (Nasdaq: LCID) filed an 8-K Monday morning disclosing an 18% reduction in its US workforce and elimination of the COO position as part of a 2026 restructuring. 12 Saudi Arabia's Public Investment Fund (PIF) remains Lucid's majority shareholder, making this restructuring a direct signal from within a sovereign wealth fund holding.

Middleby (MIDD) — tax-free Midera spin-off approved: The Middleby Corporation (Nasdaq: MIDD) board approved a tax-free spin-off of its Midera business unit with a 1-for-1 share distribution to existing Middleby shareholders. 13 Middleby, a commercial kitchen equipment manufacturer, will emerge from the transaction as a leaner entity; Midera will trade as a separate public company.

Virgin Galactic (SPCE) — 75% convertible note reduction: Virgin Galactic Holdings (NYSE: SPCE) filed an 8-K reporting a 75% reduction in its 2027 convertible notes balance, substantially cutting near-term debt obligations. 14

TopBuild / QXO proxy supplement: TopBuild (NYSE: BLD) filed an 8-K/425 supplementing its joint proxy statement for the pending QXO merger after a Delaware Court of Chancery stockholder complaint (Thompson v. QXO, Inc. et al., Case No. 2026-0757, filed June 8) alleged disclosure deficiencies. 15 The supplement discloses that Morgan Stanley received $85–$110 million in aggregate advisory fees from QXO over the prior two years, plus an estimated additional $19–$21 million for bridge facilities and related activities. Both companies deny any deficiency but are supplementing voluntarily to avoid merger delays. Special meetings for QXO and TopBuild shareholders are June 29, 2026. The board unanimously continues to recommend voting FOR the merger.

Coverage: Jun 19 1:24 PM ET → Jun 22 1:05 PM ET (21 of 21 watchlist tickers verified; 88% of broader scan confirmed).